Author/Authors :
Johnson, David W Department of Nephrology - University of Queensland - Princess Alexandra hospital - Brisbane, Australia
Abstract :
over the past 30 years, peritoneal dialysis (PD) has become
an established form of renal replacement therapy
that is currently used to treat over 200,000 patients with
end-stage renal disease worldwide (1). Patient survival on
PD is at least comparable, and possibly superior, to that
of patients receiving hemodialysis (hD) (2). however, the
rate of technique failure, including both surgical technical
and membrane failure, associated with PD is higher
than that associated with hD (3). The identification of a
biomarker that can reliably identify PD patients at high
risk of technique failure at an early stage would be highly
valuable.
